GODAVARIB Godavari Biorefineries Q3 FY26 results (Oct–Dec 2025) and concall
Godavari Biorefineries delivered a strong Q3 FY26, with robust EBITDA and PBT growth driven by improved product mix, cost management, and significant margin expansion in bio-based chemicals. The consumer brand Jivana achieved a milestone of INR 100 crores in 9M FY26, and the company secured a US patent for an anti-cancer molecule. However, the ethanol segment faced challenges from rising cane costs and a delay in grain-based distillery commissioning.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 2.9%, net profit up 33.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 321 | 447 | 580 | 533 | 431 +34% | 460 +3% |
| EBITDA | -33 | 36 | 112 | 6 | -8 +76% | 43 +19% |
| Net profit | -75 | 6 | 72 | -16 | -42 +44% | 8 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
